Navigation Links
Oncologists Rank Aloxi's Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
Date:12/4/2008

WALTHAM, Mass., Dec. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Helsinn Healthcare's Aloxi's marketing message ("Better in acute, better in delayed") is rated the most influential by oncologists in the chemotherapy-induced nausea and vomiting drug market. Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging campaign.

According to the new report entitled Brands & Strategies: Chemotherapy-Induced Nausea and Vomiting, U.S. physicians rate Aloxi higher than Merck's Emend in terms of top-of-mind therapy despite Aloxi and Emend launching in the same year in the United States. Emend scored low in terms of brand recognition with less than 20 percent of oncologists identifying the correct messages associated with the brand. Surveyed oncologists rate Emend's marketing messages ("More complete prevention comes from two directions" and "Used in more than 2.7 million chemotherapy cycles over 5 years") in the bottom three most influential messages, with the latter being the least identifiable message. Despite this, both Emend and Aloxi are forecasted to dominate the chemotherapy-induced nausea and vomiting market in 2012.

"Promotional spending on chemotherapy-induced nausea and vomiting drug therapies in the United States is relatively low compared to other therapeutic areas," said Marcus Hoyle, analyst at Decision Resources. "In 2007 $61 million was spent by the leading competitors (Merck, MGI Pharma/Eisai, Roche and Sanofi-Aventis) in the United States to promote their respective brands."

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies so they can better position themselves in a market and plan future strategy based on what competitors are doing. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to make informed decisions about their brands and next-steps.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Heather Hilty              Elizabeth Marshall
    Decision Resources         Decision Resources, Inc.
    781-296-2536               781-296-2563
    hhilty@dresources.com      emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
2. Society of Gynecologic Oncologists 39th Annual Meeting on Womens Cancer to Include Sessions on HPV and Cervical Cancer
3. South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. Society of Gynecologic Oncologists to Host 39th Annual Meeting on Womens Cancer
6. 91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs
7. Expert Neurosurgeons and Neuro-oncologists to Speak at 6th Annual Brain Tumor Awareness Day Convention
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Leading Oncologists from Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients with Cancer
10. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
11. Jefferson radiation oncologists use real-time system to plant seeds against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: